FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

850 THIRD AVENUE, 8TH FLOOR

1. Name and Address of Reporting Person*

NY

(State)

10022

(Zip)

(Street)
NEW YORK

(City)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* EDELMAN JOSEPH				BI	2. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS INC BPA]									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title Other (specify ballow))					
(Last) (First) (Middle) C/O FIRST NEW YORK SECURITIES 850 THIRD AVENUE, 8TH FLOOR					01/	3. Date of Earliest Transaction (Month/Day/Year) 01/21/2004									المادة	belov		belov	,
(Street) NEW YORK NY 10022					- 4. IT	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Application) Form filed by One Reporting Person X Person Person			son		
(City)	(S	ate) (Zip)																
4 = 11 . 6			e I - Noi	1		_			_	Dis	posed o							6 0hin	7 Notice
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		ur) E	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				4 and Secur Benef		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	() ()	() or () Price		e	Transaction(s)			(iiioaii i)	
Common Stock			01/21/2004					S		100,00	0	D	\$5.66		1,292,400		I	Through Master Fund ⁽¹⁾	
Common Stock			01/21/2004		,			S		15,000	0	D	\$5.84		1,277,400		I	Through Master Fund ⁽¹⁾	
Common Stock			01/21/2004		ļ.			S		5,000		D	\$5.65		1,272,400		I	Through Master Fund ⁽¹⁾	
Common Stock			01/22/2004					S		100,00	0	D	\$5.68		1,172,400		I	Through Master Fund ⁽¹⁾	
Common Stock			01/23/2004					S		35,000		D	\$5.62		1,137,400		I	Through Master Fund ⁽¹⁾	
Common Stock															225,000		D ⁽²⁾		
		Та						•		•	sed of, onvertib				•	vned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	ed Date,	4. Transa Code (8)	ction	5. Nu of	mber rative rities ired r osed		xercis n Date	ate Amount of De Year) Securities Se		8. Pi		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)		Date Exercisal		Expiration Date	Title	or	ount nber ires					
1. Name and Address of Reporting Person* <u>EDELMAN JOSEPH</u>																			
(Last) (First) (Middle) C/O FIRST NEW YORK SECURITIES					_														

PERCEPTIVE FUND LTD	LIFE SCII	ENCES MASTER						
(Last)	(First)	(Middle)						
5437 CONNECTICUT AVE NW STE 100								
(Street)								
WASHINGTON	DC	20015						
(City)	(State)	(Zip)						
1. Name and Address of Reporting Person* PERCEPTIVE ADVISORS LLC								
(Last)	(First)	(Middle)						
PERCEPTIVE CA	PITAL							
5437 CONNECTICUT AVENUE NW STE 100								
(Street)								
WASHINGTON	DC	20015						
(City)	(State)	(Zip)						

Explanation of Responses:

1. This transaction was effected through Perceptive Life Sciences Master Fund ("Master Fund"). Master Fund and its investment advisor, Perceptive Advisors"), are jointly filing this statement with Mr. Edelman, the managing member of Advisors, as described on the Joint Filer Information Statement attached as an exhibit hereto. In accordance with Instruction 4(b)(ty) to Form 4, the entire amount of the Issuer's securities held by Master Fund is reported herein. Mr. Edelman and Advisors each disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, beneficial ownership of any such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman or Advisors is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

2. These shares are held directly by Mr. Edelman.

Joseph Edelman 01/23/2004

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Joint Filer Information

Names: Perceptive Life Sciences Master Fund Ltd. and

Perceptive Advisors LLC

IRS I.D. No.: 980338943 (Master Fund) 52-2291758 (Advisors)

Address: c/o First New York Securities, LLC

850 Third Avenue, 8th Floor New York, New York 10022

Designated Filer: Joseph Edelman

Issuer and Ticker Symbol: Biosante Pharmaceuticals, Inc. (BPA)

Date of Earliest Transaction January 21, 2004

(Month/Day/Year)

The undersigned, Perceptive Life Sciences Master Fund Ltd. and Perceptive Advisors LLC are jointly filing the attached Initial Statement of Beneficial Ownership on Form 4 with Joseph Edelman with respect to the beneficial ownership of securities of Biosante Pharmaceuticals, Inc.

PERCEPTIVE LIFE SCIENCES

PERCEPTIVE ADVISORS LLC

MASTER FUND LTD.

By: Perceptive Advisors LLC, its

investment advisor

By: /s/ Joseph Edelman By: /s/ Joseph Edelman

Name: Joseph Edelman
Title: Managing Member

Name: Joseph Edelman
Title: Managing Member